Moderna shares surge after it says its experimental mRNA cancer treatment passed a key test
Moderna shares more than doubled Wednesday after it announced initial results from a study of an experimental cancer treatment that would be the first of its kind if approved by regulators. Moderna and Merck are developing a treatment using an mRNA-based cancer vaccine called intismeran that is designed to be tailored to individual patients based […]
Moderna's stock price more than doubled on Wednesday following the announcement of positive initial results from a study of an experimental cancer treatment. The treatment, a mRNA-based cancer vaccine named intismeran, is being developed in collaboration with Merck and is set to be individualized for each patient based on their unique tumor mutations.
Intismeran is being tested in conjunction with Merck's immunotherapy drug, Keytruda. In the current study, patients who received the combination of intismeran and Keytruda showed longer survival rates without cancer recurrence or metastasis compared to those who received Keytruda alone. However, the exact duration of survival and overall survival rates were not disclosed by the companies.
They plan to present the study findings at an upcoming international medical conference. Moderna's shares surged over 120% to reach $140.12 per share, while Merck's shares increased by around 11%.
Written by urgent.news from CityNews's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
